Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2025)

Lyell Immunopharma's EBITDA Margin history spans 6 years, with the latest figure at 258013.33% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 13028980.0% year-over-year to 258013.33%; the TTM value through Sep 2025 reached 795656.1%, down 47494499.0%, while the annual FY2024 figure was 561654.1%, 38694102.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 258013.33% at Lyell Immunopharma, up from 534812.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 12.4% in Q4 2022 and bottomed at 2396633.33% in Q3 2022.
  • The 5-year median for EBITDA Margin is 198620.0% (2023), against an average of 481436.95%.
  • The largest annual shift saw EBITDA Margin crashed -239485428bps in 2022 before it surged 219801333bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 3021.4% in 2021, then soared by 100bps to 12.4% in 2022, then tumbled by -3215894bps to 398792.31% in 2023, then tumbled by -339bps to 1749127.27% in 2024, then soared by 85bps to 258013.33% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's EBITDA Margin are 258013.33% (Q3 2025), 534812.5% (Q2 2025), and 747542.86% (Q1 2025).